Cargando…

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

OBJECTIVE: The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm of non-small cell lung cancer (NSCLC). Despite the durability of response to ICIs, the vast majority of patients will later develop progression. However, the failure patterns of ICI treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chai, Rong, Yin, Yipengchen, Cai, Xuwei, Fu, Xiaolong, Zhang, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454403/ https://www.ncbi.nlm.nih.gov/pubmed/34557412 http://dx.doi.org/10.3389/fonc.2021.724722

Ejemplares similares

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
por: Li, Feng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
por: Jessel, Shlomit, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer
por: Asano, Yohei, et al.
Publicado: (2022)

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review
por: Shen, Jingjing, et al.
Publicado: (2022)

Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
por: Diker, Omer, et al.
Publicado: (2023)

A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy
por: Vilas-Boas, Isabel, et al.
Publicado: (2022)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
por: Wan, Mingyu, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
por: Aly, Ragia, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region
por: Nieder, Carsten, et al.
Publicado: (2020)

The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
por: Li, Sihan, et al.
Publicado: (2021)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
por: Kiss, Igor, et al.
Publicado: (2022)

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC
por: Wang, Qian, et al.
Publicado: (2023)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
por: Zhu, Ke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_altl395q3omhhvcjievevhbtoh